The company maintains a liquid position with $54.2M in cash, though this is offset by a substantial accumulated deficit in retained earnings totaling $103.6M.
| Total Current Assets | 68.56M | 79.01M | 50.25M | 1.92M | 2.33M | 12.17M | 7.7M |
| Cash & Short-Term Investments | - | - | - | - | - | - | - |
| Cash Only | - | - | - | - | - | - | - |
| Short-Term Investments | - | - | - | - | - | - | - |
| Accounts Receivable | - | - | - | - | - | - | - |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 4.69M | 3.55M | 17.87K | 366.32K | 0 | 0 | 0 |
| Total Non-Current Assets | 691.51K | 719.96K | 485.76K | 533.73K | 618.21K | 709.76K | 735.97K |
| Property, Plant & Equipment | 0 | 328.54K | 27.08K | 1.72K | 3.82K | 13K | 6.84K |
| Fixed Asset Turnover | 107.96x | 31.11x | - | - | - | - | - |
| Goodwill | 0 | 391.42K | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 386.04K | 0 | 412.97K | 532.01K | 614.39K | 696.76K | 729.14K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | - | - | - | - | - | - | - |
| Total Assets | 69.25M | 79.73M | 50.74M | 2.45M | 2.95M | 12.88M | 8.44M |
| Asset Turnover | 0.18x | 0.13x | - | - | - | - | - |
| Asset Growth % | 2987.75% | 57.14% | 1969.06% | -16.9% | -77.09% | 52.68% | - |
| Total Current Liabilities | 5.43M | 9.13M | 3.35M | 2.62M | 4.06M | 1.8M | 3.58M |
| Accounts Payable | 0 | 8.98M | 872.68K | 0 | 2.02M | 454.99K | 27.54K |
| Days Payables Outstanding | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 911.46K | 1.22M | 1.21M | 1.08M | 24K |
| Deferred Revenue (Current) | 0 | - | - | - | - | - | - |
| Other Current Liabilities | 5.31M | 0 | 643.06K | 602.84K | 550.66K | 0 | 3.34M |
| Current Ratio | 12.64x | 8.65x | 15.00x | 0.73x | 0.58x | 6.75x | 2.15x |
| Quick Ratio | 12.64x | 8.65x | 15.00x | 0.73x | 0.58x | 6.75x | 2.15x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 6.37M | 8.07M | 5.92M | 4.54M | 214.28K | 2.05M | 4.84M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 3.19M |
| Capital Lease Obligations | 0 | - | - | - | - | - | - |
| Deferred Tax Liabilities | 0 | - | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - | - | - |
| Total Liabilities | 11.79M | 17.2M | 9.27M | 7.16M | 4.27M | 3.85M | 8.42M |
| Total Debt | 0 | 0 | 911.46K | 1.22M | 1.21M | 1.08M | 3.22M |
| Net Debt | -54.25M | -66.11M | -47.63M | -274.2K | -872.23K | -10.23M | -2.71M |
| Debt / Equity | 0.00x | - | 0.02x | - | - | 0.12x | 200.84x |
| Debt / EBITDA | -0.00x | - | - | - | - | - | - |
| Net Debt / EBITDA | 2.01x | - | - | - | - | - | - |
| Interest Coverage | - | - | -77.79x | -202.40x | -69.08x | -36.01x | -6.51x |
| Total Equity | 57.46M | 62.53M | 41.46M | -4.71M | -1.32M | 9.03M | 16.01K |
| Equity Growth % | 3742.16% | 50.81% | 979.83% | -256.97% | -114.62% | 56306.74% | - |
| Book Value per Share | 2.62 | 3.54 | 5.72 | -1.31 | -0.49 | 4.23 | 0.01 |
| Total Shareholders' Equity | 57.46M | 62.53M | 41.46M | -4.71M | -1.32M | 9.03M | 16.01K |
| Common Stock | 133.95M | 133.89M | 99.13M | 50.35M | 40.26M | 40.01M | 14.57M |
| Retained Earnings | -103.58M | -97.11M | -76.29M | -63.35M | -49.99M | -38.03M | -18.49M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -104.3K | -104.3K | -104.3K | 8.29M | 8.41M | 7.05M | 3.94M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Commercial execution and liquidity
According to recent balance sheet data, Alpha Cognition has grown its total assets to $69.2M as of 2026Q1, yet this expansion is primarily fueled by external financing rather than organic value creation, as evidenced by the persistent accumulation of a $103.6M deficit in retained earnings.
The trajectory of the balance sheet reflects a company in a high-stakes transition phase where asset growth is decoupled from operational profitability. Investors should monitor whether the current asset base can be leveraged to generate sufficient commercial returns before the accumulated deficit further erodes the equity position.
As reported in financial statements, the company maintains a cash position of $54.2M in 2026Q1, which provides a necessary buffer for operations, though the rapid decline from $66.1M in 2025Q4 suggests that the current burn rate may necessitate additional capital infusions within the next year.
While the current ratio of 12.64 appears robust, it is heavily skewed by the cash balance relative to minimal current liabilities, masking the underlying reality of high operational cash outflows. The company's liquidity profile remains highly sensitive to the success of its commercial launch, as any delay in revenue scaling will accelerate the depletion of these reserves.
Based on the company's reported figures, equity has fluctuated significantly, reaching $57.5M in 2026Q1, a trend that underscores the volatility inherent in a clinical-stage entity that has historically relied on equity financing to offset substantial operating losses and negative retained earnings.
The quality of equity is currently constrained by the massive accumulated deficit, which suggests that shareholders are bearing the full brunt of the company's R&D and commercialization costs. Future equity stability will likely depend on the company's ability to demonstrate a path toward positive net income, thereby arresting the ongoing erosion of book value.
Analysis of the balance sheet reveals that the company's asset base is almost entirely composed of cash, with negligible tangible assets or PPE, which may indicate that the firm's true value is tied to intangible intellectual property that is not fully captured on the balance sheet.
The lack of significant PPE suggests an asset-light model that is highly dependent on the successful commercialization of its prodrug technology. Investors should be wary that the headline asset figures provide little protection in a downside scenario, as the company's value is almost exclusively tied to the future market potential of its pipeline.
Quick answers to the most common questions about buying ACOG stock.
As of 2025, Alpha Cognition Inc. Common Stock (ACOG) had total assets of $79.7M including $79.0M in current assets.
Alpha Cognition Inc. Common Stock (ACOG) carries total debt of $0.0M. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Alpha Cognition Inc. Common Stock (ACOG) has total shareholders' equity (book value) of $62.5M ($3.54 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Alpha Cognition Inc. Common Stock (ACOG) reported a current ratio of 8.65x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.